Genoskin raises $8.7M to advance immunocompetent human skin models

16 September 2025

Franco-American CRO Genoskin announces it has raised $8.7M in its first funding round led by OCCTE (FPCI Occidev Impacts) to grow its human ex vivo skin platform.

In a field that struggles to bridge the gap between preclinical promise and clinical outcome, the project carried by Genoskin has a particular significance. The development of vaccines and therapies for human skin diseases is fraught with difficulties, not least of which is the existence of numerous inter-species differences in skin anatomy, physiology and immunity.

To address this challenge, Toulouse-based Genoskin develops and supplies immunocompetent ex vivo skin models that enable more predictive, human-relevant testing than traditional animal or engineered models. By employing AI-powered multi-omics analyses, Genoskin supports global pharma, biotech and cosmetics companies with meaningful insights into mechanisms of human skin pathologies, reliable safety and efficacy assessments, and accelerated regulatory acceptance.

A notable example is the company's partnership with Catalyst Biosciences to mitigate pain and redness observed at injection site of DalcA treatment in patients with Hemophilia B. Genoskin's ISR platform® was the first human skin ex vivo platform to study injection site reactions to vaccines and drug candidates. By leveraging Genoskin's HypoSkin® ex vivo model and expertise in immunotoxicity assays,  Catalyst Biosciences was able to identify a new formulation buffer for DalcA with a lower risk of injection site reactions.

“As a company built on ethical innovation, we are proud to offer sustainable, human-relevant alternatives to animal testing. This investment validates our strategy and reinforces our position as a leader in predictive immunotoxicology using live human skin models,” stressed Pascal Descargues, CEO of Genoskin.  

This first round of funding will further support the company's launching of new immune-centric services, scaling up of operations through automation, increase in production capacity, and expansion of commercial presence in key global markets.

For weekly news, trends and insights on human‑based in vitro approaches, explore your access options.

Explore Access